Ebene Magazine – B. Riley Comments on Zynex, Inc. Third Quarter 2021 Earnings (NASDAQ: ZYXI)


Log in to MarketBeat All Access to get access to all of MarketBeat’s research:

Zynex, Inc. (NASDAQ: ZYXI) – B. Riley’s stock researchers announced in a Friday On February 26, the report released its estimates for earnings per share (EPS) for Zynex lowered in the third quarter of 2021. B. Riley analyst M. Wiesenberger now expects the company to post earnings per share of $ 0.10 for the quarter, compared to its previous forecast of $ 0.16. B. Riley has a « neutral » rating and a target price of $ 19.00 on the stock. B. Riley also released estimates of Zynex’s earnings for the fourth quarter of 2021 at $ 0.20 per share and for fiscal year 2222 at $ 0.79 per share.

Other equity analysts have also published reports on the company. Piper Sandler downgraded Zynex in a research note on Friday, January 29th, from an « overweight » rating to a « neutral » rating and lowered the price target for the stock from $ 28.00 to $ 20.00. Northland Securities downgraded Zynex from an « Outperform » rating to a « Market Perform » rating and set a price target of $ 22.50 on the stock. in a research report on Thursday, January 28th. Four investment analysts have rated the stock with a hold rating and one with a buy rating. The company has an average « hold » rating and a consensus price target of $ 19.70.

Zynex stock opened at $ 14.52 on Monday. The company’s 50-day moving average price is $ 17.80 and the two-hundred-day moving average is $ 14.68. Zynex has a 12-month low of $ 7.93 and a 12-month high of $ 29.73. The stock has a market cap of $ 504.44 million, a P / E of 44.00, and a beta of 0.60. The company has a fast rate of 4.17, a current rate of 4.96, and a leverage ratio of 0.01. Zynex (NASDAQ: ZYXI) last released its quarterly results on Thursday, February 25th. The company reported earnings per share of $ 0.05 for the quarter, falling short of Zacks’ consensus estimate of $ 0.06 ($ 0.01). Zynex had a return on equity of 50.67% and a net margin of 18.08%. (adsbygoogle = window.adsbygoogle || []). push ({});

Hedge funds and other institutional investors recently increased or decreased their stake in the company. The New York State Common Retirement Fund increased its stake in Zynex shares by 156.5% in the third quarter. The New York State Common Retirement Fund now owns 36,678 shares of the company valued at $ 640,000 after purchasing an additional 22,378 shares last quarter. Nisa Investment Advisors LLC purchased a new stake in Zynex worth $ 127,000 in the third quarter. Principal Financial Group Inc. increased its stake in Zynex by 21.9% in the third quarter. Principal Financial Group Inc. now owns 139,017 shares in the company valued at $ 2,426,000 after purchasing an additional 24,976 shares last quarter. Catalyst Capital Advisors LLC increased its stake in Zynex by 54.1% in the fourth quarter. Catalyst Capital Advisors LLC now owns 23,500 shares in the company valued at $ 316,000 after purchasing an additional 8,250 shares last quarter. Finally, Manufacturers Life Insurance Company increased its stake in Zynex by 15.0% in the third quarter. Manufacturers Life Insurance Company now owns 67,828 shares in the company valued at $ 1,184,000 after purchasing an additional 8,844 shares last quarter. Hedge funds and other institutional investors own 29.57% of the company’s shares.

Zynex, Inc develops, manufactures and markets medical devices for the treatment of chronic and acute pain through its subsidiaries. and activate and train muscles for rehabilitation purposes with electrical stimulation. It offers NexWave, a two-channel interference current with multiple modalities, a transcutaneous electrical nerve stimulation (TENS) and a neuromuscular electrical stimulation device. NeuroMove, an electrical stimulation device triggered by electromyography; InWave, an electrical stimulation product used to treat female urinary incontinence; and TENSWave, a two-channel TENS device.

This instant messaging alert was generated using narrative science technology and financial data from MarketBeat to give readers the fastest, most accurate coverage possible. This story has been reviewed by the editorial staff of MarketBeat prior to publication. Please send questions or comments about this story to [email protected]

If you’re anything like me, then Christmas always has a way to sneak up on you. And once you get to Christmas, the end of the year is only a week away. For investors, 2020 ends with the volatility it started with. And it wasn’t much quieter in between.

Whether you are faced with deciding where to allocate IRA contributions or just want to spend some time realigning your portfolio this holiday season, you may be wondering which stocks to buy next January . It will be a time when there is much hope, but a real normal will be months away. What should i do?

My advice to you is to keep it simple. And that’s exactly what I’m trying to do in this particular presentation. I’m not trying to trip you down or send you down the rabbit hole with any secret speculative inventory. I want to buy into companies that appear to be good buys as the economy picks up.

Fill out the form below to receive the latest headlines and analyst recommendations for your stocks with our free daily email newsletter:

Sign up to MarketBeat All Access to access the full Get Research Tools from MarketBeat:

View the latest news, buy / sell ratings, SEC filings, and insider deals for your stocks. Compare your portfolio performance against leading indices and get personalized stock ideas based on your portfolio.

Get stock ideas daily with the best Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. See what stocks are up to date on social media with MarketBeat’s Trending Stock Report.

Identify stocks that match your criteria using seven unique stock screeners. See what’s happening in the market with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access Stock Screener, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Would you like to see which stocks are moving? View our full range of financial calendars and market data tables for free.

Receive free world class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat enables individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, company buybacks, dividends, earnings, business reports, financial data, insider trading, IPOs, SEC filings, or stock splits, MarketBeat has the objective information you need to analyze stocks. Learn more.

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St # 105, Sioux Falls, SD 57103 | [Email protected] | (844) 978-6257
MarketBeat does not provide financial advice or make recommendations or offers to buy stocks or sell any securities. Learn more.
Don’t sell my information

© 2021 The market data provided will be delayed by at least 10 minutes and hosted by Barchart Solutions. The information is provided « as is » and is provided for informational purposes only, not for commercial or advisory purposes, and is delayed. Please refer to the disclaimer for all delays and terms of use for exchanges. Basic company data from Zacks Investment Research. As a bonus for subscribing to our e-mail newsletters, you will also receive a free subscription to the Liberty Through Wealth e-newsletter. You can unsubscribe at any time.

Enter your email address below to receive a quick daily summary of upgrades, downgrades, and new coverage from Analysts with MarketBeat.com’s FREE daily email newsletter.

Ref: https://www.marketbeat.com




Laisser un commentaire, votre avis compte!


Laisser un commentaire, votre avis compte!

Laisser un commentaire, votre avis compte!